#ACR19 Abst#2878 #ACRbest - Tildrakizumab (IL23i) RCT Good ACR20 (80% v 51%, NNT ~3) regardless of dose; great safety profile. Curiously high PLBO response, expectation bias? PASI75 phenomenal per usual (80% v 17% plbo, NNT 1-2) Need IL23/IL17/TNF comparative study! @RheumNow https://t.co/uEGvsD8KVb